3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
Janux Therapeutics Inc JANX
$15.17
▼ -2.63%
($-0.41)
🎢 High Beta
📅 Earnings This Week
Open
$15.55
Prev Close
$15.58
Day Range
$15.00 – $15.56
52W Range
$12.12 – $35.34
Market Cap
$925.13M
Beta
2.54
EPS (TTM)
$-1.84
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-06-11 |
| Shares Out. | 60,980,000 |
| Website | januxrx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 108 |
| Revenue | $3.7M |
| Gross Profit | $3.7M |
| Net Income | -$24.4M |
| Free Cash Flow | -$78.5M |
| Total Assets | $1.03B |
| Total Liabilities | $86.7M |
| Equity | $941.5M |
About Janux Therapeutics Inc
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Janux Therapeutics Inc is a publicly traded company under the ticker symbol JANX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
26 analysts (2026-07-01)